(TRVI) Trevi Therapeutics - Ratings and Ratios

Trevi Therapeutics, Inc. (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company focused on developing treatments for chronic cough conditions. Their lead product, Haduvio, is an oral extended-release formulation of nalbuphine, an opioid agonist-antagonist. It targets chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), leveraging its mechanism on both central and peripheral nervous systems. Currently, Haduvio is in Phase 2b for IPF, Phase 2a for RCC, and other trials for pruritus and prurigo nodularis. Trevi has a licensing agreement with Endo Pharmaceuticals for nalbuphine-based products. Founded in 2011, the company is headquartered in New Haven, Connecticut.

From a technical standpoint, TRVIs stock is currently priced at $4.50, above its 20-day SMA ($4.25) and 50-day SMA ($4.13), but below the 200-day SMA ($3.21), suggesting a short-term uptrend within a broader downtrend. The average true range (ATR) of 0.30 indicates moderate volatility.

Fundamentally, Trevis market cap is $411.08M with a high P/B ratio of 7.27, reflecting investor confidence despite a negative RoE of -75.15%, typical for a clinical-stage biotech. The companys valuation hinges on potential growth from its pipeline.

Technically, TRVI may find support near its 20 and 50-day SMAs ($4.25 and $4.13), with resistance at the 200-day SMA ($3.21). The moderate ATR suggests price swings will remain manageable. Fundamentally, while the high P/B ratio indicates investor optimism, the negative RoE highlights the need for positive clinical developments. In the next quarter, TRVI is likely to trade sideways, potentially breaking out on positive trial news or remaining range-bound otherwise.